Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Feb 26:7:3.
doi: 10.1186/1471-2415-7-3.

TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD

Francis E Cangemi  1
Affiliations
Randomized Controlled Trial

TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD

Francis E Cangemi. BMC Ophthalmol. .

Abstract

Background: The primary objective of this prospective study was to measure the change from baseline in visual function--Best-Corrected Visual Acuity (BCVA) via the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, contrast sensitivity, central 10 degree visual fields and retinal imaging (angiograms and photographs) at 6 months in subjects with atrophic (dry) age-related macular degeneration treated with a targeted nutritional supplement.

Methods: 37 mixed gender patients with a mean age of 76.3 +/- 7.8 years were enrolled at 5 independent study sites and received standard of care with a novel formulation of a nutritional supplement. Results were compared to a placebo cohort constructed from the literature that was matched for inclusion and exclusion criteria. A paired t-test was used to test a null hypothesis and a two-sided alpha level of 0.05 was used to determine statistical significance.

Results: 76.7% of subjects receiving the nutritional supplement demonstrated stabilization or improvement of BCVA at 6 months. Subjects gained an average of 0.0541 logMAR or one-half of a line of visual acuity (VA) over the 6-month period. There was a statistically significant improvement in VA from baseline with P = .045. The results provide strong evidence that the treatment being studied produces an improvement in VA.

Conclusion: Treatment with this unique nutritional supplement increased VA above the expected baseline decrease in the majority of patients in this population with dry macular degeneration. The results of the TOZAL study agree with the LAST and CARMIS studies and are predictive for positive visual acuity outcomes in the AREDS II trial. However, patients will likely require supplementation for longer than 6 months to effect changes in additional visual parameters.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study design.
Figure 2
Figure 2
Mean ETDRS line change at 3 and 6 months.
Figure 3
Figure 3
Percent of subjects with improved or maintained BCVA at 6 months.
Figure 4
Figure 4
Average (and 95% CI for average) visual acuity at baseline and at follow-up.
See this image and copyright information in PMC

References

    1. National Eye Institute. Vision problems in the US. 2006. http://www.nei.nih.gov/eyedata
    1. Weeks DE, Conley YP, Tsai HJ. Age-related maculopathy: an expanded genome-wide scan with evidence of susceptibility loci within the 1q31 and 17q25 regions. Am J Ophthalmol. 2001;132:682–692. doi: 10.1016/S0002-9394(01)01214-4. - DOI - PubMed
    1. Christen WG, Glynn RJ, Manson JE, Ajani UA, Burning JE. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA. 1996;276:1147–1151. doi: 10.1001/jama.276.14.1147. - DOI - PubMed
    1. Seddon J, Willett W, Speizer F. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA. 1996;276:1141–1146. doi: 10.1001/jama.276.14.1141. - DOI - PubMed
    1. Newsome DA, Swartz M, Leone NC, Elston RC, Miller E. Oral zinc in macular degeneration. Arch Ophthalmol. 1988;106:192–198. - PubMed

Publication types

MeSH terms